-0.000246102060906247 0.00020736083325388 0.00131116827029938 0.000476326569495974 0.00147661236543766 -0.00139722460385506 0.00107967355752429 0.00479502079959351
Sign Up Today X
Thanks for submitting the form.
Stockreport

BMS expands Krazati's FDA label to include colorectal cancer [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
The drug's approved use will be in combination with Eli Lilly's epidermal growth factor receptor (EGFR) antagonist Erbitux (cetuximab). Krazati gained US FDA accelerated approval as a second-line treatment of KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2022. Krazati's conditional approval in colorectal cancer was based on data from the open-label Phase I/II KRYSTAL-1 trial (NCT03785249). The study evaluated the Krazati and Erbitux combination therapy in 94 patients with KRAS-mutated colorectal cancer. The study met its primary endpoint with an overall response rate of 34%, all of which were partial responses. The median duration of response was 5.8 months. Serious adverse reactions occurred in 30% of the trial participants. The most common adverse events included non-specific side effects like rash, nausea, diarrhoea, vomiting and fatigue along with liver toxicity, anaemia and peripheral neuropathy. Krazati targets an altered protein produc [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

BMS expands Krazati's FDA label to include colorectal cancer [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
The drug's approved use will be in combination with Eli Lilly's epidermal growth factor receptor (EGFR) antagonist Erbitux (cetuximab). Krazati gained US FDA accelerated approval as a second-line treatment of KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2022. Krazati's conditional approval in colorectal cancer was based on data from the open-label Phase I/II KRYSTAL-1 trial (NCT03785249). The study evaluated the Krazati and Erbitux combination therapy in 94 patients with KRAS-mutated colorectal cancer. The study met its primary endpoint with an overall response rate of 34%, all of which were partial responses. The median duration of response was 5.8 months. Serious adverse reactions occurred in 30% of the trial participants. The most common adverse events included non-specific side effects like rash, nausea, diarrhoea, vomiting and fatigue along with liver toxicity, anaemia and peripheral neuropathy. Krazati targets an altered protein produc [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS